CAR-T Therapies: Access Considerations May Influence US FDA's Efficacy Evaluation

 
• By Sarah Karlin-Smith

CBER's Lola Fashoyin-Aje offers some thoughts on when and how the FDA might consider the accessibility of a product in its approval decisions at BIO 2024.

3d illustration of a T cell attacking a cancer cell
US FDA discusses efficacy and access trade-offs for CAR-T therapies. • Source: Shutterstock

More from Approval Standards

More from Pathways & Standards